Search results
Results from the WOW.Com Content Network
After 670 days, there were 1,172 new diagnoses of dementia among the study participants. When compared with people who took DPP-4 inhibitors, those who took SGLT-2 inhibitors had a 35 percent ...
There are different classes of hypoglycemic drugs, and selection of the appropriate agent depends on the nature of diabetes, age, and situation of the person, as well as other patient factors. Diabetes mellitus type 1 is a disease caused by the lack of insulin. Thus, Insulin is the main treatment agent for type 1 and is typically administered ...
The results of a new large-scale study published in The BMJ suggest that a relatively new diabetes drug might reduce the risk of developing dementia in people with type 2 diabetes. Taking SGLT-2 ...
Diabetes mellitus, often known simply as diabetes, is a group of common endocrine diseases characterized by sustained high blood sugar levels. [10][11] Diabetes is due to either the pancreas not producing enough insulin, or the cells of the body becoming unresponsive to the hormone's effects. [12] Classic symptoms include thirst, polyuria ...
Insulin was first used as a medication in Canada by Charles Best and Frederick Banting in 1922. [13][14] This is a chronology of key milestones in the history of the medical use of insulin. For more details on the discovery, extraction, purification, clinical use, and synthesis of insulin, see Insulin. 1921 Research on the role of pancreas in ...
Thiazolidinedione. The thiazolidinediones / θaɪ.əˌzoʊlɪdiːnˈdaɪ.oʊn /, abbreviated as TZD, also known as glitazones after the prototypical drug ciglitazone, [1] are a class of heterocyclic compounds consisting of a five-membered C 3 NS ring. The term usually refers to a family of drugs used in the treatment of diabetes mellitus type 2 ...
The type 2 diabetes drug metformin helped slow aging across multiple organs, including the brain, kidneys, and the skin, a study in cynomolgus monkeys has shows. Common diabetes drug may help slow ...
[46] [47] It was given the brand name Ozempic. Clinical trials started in January 2016 and ended in May 2017. [19] [48] The US Food and Drug Administration (FDA) approved semaglutide based on evidence from seven clinical trials of 4087 participants with type 2 diabetes. [25]